These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19626587)

  • 21. Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity.
    Awasthi S; Singhal SS; Singhal J; Yang Y; Zimniak P; Awasthi YC
    Int J Oncol; 2003 Apr; 22(4):721-32. PubMed ID: 12632061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Role and clinical significance of RLIP76 in regulation of multi-drug resistance of small cell lung cancer].
    Haixia P; Yifeng B; Honglin H
    Zhonghua Zhong Liu Za Zhi; 2015 Apr; 37(4):266-71. PubMed ID: 26462890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RLIP76 (RALBP1)-mediated transport of leukotriene C4 (LTC4) in cancer cells: implications in drug resistance.
    Sharma R; Singhal SS; Wickramarachchi D; Awasthi YC; Awasthi S
    Int J Cancer; 2004 Dec; 112(6):934-42. PubMed ID: 15386349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.
    Hipp MM; Hilf N; Walter S; Werth D; Brauer KM; Radsak MP; Weinschenk T; Singh-Jasuja H; Brossart P
    Blood; 2008 Jun; 111(12):5610-20. PubMed ID: 18310500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro.
    Krusch M; Salih J; Schlicke M; Baessler T; Kampa KM; Mayer F; Salih HR
    J Immunol; 2009 Dec; 183(12):8286-94. PubMed ID: 20007592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
    Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
    Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
    Bil J; Zapala L; Nowis D; Jakobisiak M; Golab J
    Cancer Lett; 2010 Feb; 288(1):57-67. PubMed ID: 19632769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New use for an old drug: inhibiting ABCG2 with sorafenib.
    Wei Y; Ma Y; Zhao Q; Ren Z; Li Y; Hou T; Peng H
    Mol Cancer Ther; 2012 Aug; 11(8):1693-702. PubMed ID: 22593228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RLIP76 is the major ATP-dependent transporter of glutathione-conjugates and doxorubicin in human erythrocytes.
    Sharma R; Singhal SS; Cheng J; Yang Y; Sharma A; Zimniak P; Awasthi S; Awasthi YC
    Arch Biochem Biophys; 2001 Jul; 391(2):171-9. PubMed ID: 11437348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regression of prostate cancer xenografts by RLIP76 depletion.
    Singhal SS; Roth C; Leake K; Singhal J; Yadav S; Awasthi S
    Biochem Pharmacol; 2009 Mar; 77(6):1074-83. PubMed ID: 19073149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
    Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
    Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RLIP76 is a major determinant of radiation sensitivity.
    Awasthi S; Singhal SS; Yadav S; Singhal J; Drake K; Nadkar A; Zajac E; Wickramarachchi D; Rowe N; Yacoub A; Boor P; Dwivedi S; Dent P; Jarman WE; John B; Awasthi YC
    Cancer Res; 2005 Jul; 65(14):6022-8. PubMed ID: 16024601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Poller B; Wagenaar E; Tang SC; Schinkel AH
    Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Leung HW; Chan AL
    Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RLIP76 is overexpressed in human glioblastomas and is required for proliferation, tumorigenesis and suppression of apoptosis.
    Wang Q; Wang JY; Zhang XP; Lv ZW; Fu D; Lu YC; Hu GH; Luo C; Chen JX
    Carcinogenesis; 2013 Apr; 34(4):916-26. PubMed ID: 23276796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased expression of cdc2 inhibits transport function of RLIP76 and promotes apoptosis.
    Singhal SS; Yadav S; Vatsyayan R; Chaudhary P; Borvak J; Singhal J; Awasthi S
    Cancer Lett; 2009 Oct; 283(2):152-8. PubMed ID: 19375851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of RLIP76 in lung cancer doxorubicin resistance: II. Doxorubicin transport in lung cancer by RLIP76.
    Awasthi S; Singhal SS; Singhal J; Cheng J; Zimniak P; Awasthi YC
    Int J Oncol; 2003 Apr; 22(4):713-20. PubMed ID: 12632060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
    Tochizawa S; Masumori N; Yanai Y; Ohmoto Y; Yabuuchi Y; Tsukamoto T
    Biomed Res; 2008 Dec; 29(6):271-8. PubMed ID: 19129670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.